Erschienen in:
01.12.2001 | Adis New Drug Profile
Tegafur/Uracil
A Viewpoint by Tomoyuki Kato
verfasst von:
Tomoyuki Kato
Erschienen in:
Drugs & Aging
|
Ausgabe 12/2001
Einloggen, um Zugang zu erhalten
Excerpt
Tegafur/uracil, an oral combination of tegafur and uracil at a molar ratio of 1:4, produces prolonged concentrations of fluorouracil (converted from tegafur) in tumours due to the inhibition of fluorouracil degradation by uracil. Tegafur/uracil is the first of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. The drug is effective in patients with gastrointestinal cancer, hepatobiliary cancer, breast cancer and lung cancer. The overall response rate of tegafur/uracil for advanced colorectal cancer is approximately 25%.[
1] …